Bhoj Elizabeth J, Yu Zhenming, Guan Qiaoning, Ahrens-Nicklas Rebecca, Cao Kajia, Luo Minjie, Tischler Tanya, Deardorff Matthew A, Zackai Elaine, Santani Avni B
Division of Genomic Diagnostics and Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Genet Med. 2017 Jun;19(6):715-718. doi: 10.1038/gim.2016.169. Epub 2016 Oct 20.
RASopathies include disorders generally characterized by developmental delay, specific heart defects, short stature, cardiac hypertrophy, and facial dysmorphisms. Next-generation sequencing (NGS)-based panels have widespread acceptance as a diagnostic tool for RASopathies.
The first 126 patients evaluated by clinical examination and the NGS RASopathy panel at the Children's Hospital of Philadelphia were enrolled. We calculated diagnosis rate, correlated reported clinical findings with positive or negative test results, and identified final molecular diagnoses in 28/96 patients who tested negative for RASopathies.
Twenty-four patients had pathogenic variants on the RASopathy panel, for a diagnostic yield of 19%. Reported features of pulmonic stenosis and ptosis were significantly correlated with a positive test result; no reported features were significantly correlated with a negative test result. We identified 27 different alternative diagnoses for patients originally suspected of having RASopathies.
This study provides information that can assist in guiding differential diagnosis and genetic testing for patients suspected of having a RASopathy disorder.Genet Med advance online publication 20 October 2016.
RAS病包括一类通常具有发育迟缓、特定心脏缺陷、身材矮小、心脏肥大和面部畸形等特征的疾病。基于二代测序(NGS)的检测组合作为RAS病的诊断工具已被广泛接受。
纳入费城儿童医院首批126例经临床检查和NGS RAS病检测组合评估的患者。我们计算了诊断率,将报告的临床发现与检测结果的阳性或阴性进行关联,并在96例RAS病检测结果为阴性的患者中确定了28例患者的最终分子诊断。
24例患者在RAS病检测组合上发现了致病变异,诊断率为19%。报告的肺动脉狭窄和上睑下垂特征与检测结果阳性显著相关;没有报告的特征与检测结果阴性显著相关。我们为最初怀疑患有RAS病的患者确定了27种不同的其他诊断。
本研究提供的信息有助于指导对疑似患有RAS病的患者进行鉴别诊断和基因检测。《遗传医学》2016年10月20日在线优先发表。